248 related articles for article (PubMed ID: 34535643)
1. Activation mechanism of human soluble guanylate cyclase by stimulators and activators.
Liu R; Kang Y; Chen L
Nat Commun; 2021 Sep; 12(1):5492. PubMed ID: 34535643
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs.
Næsheim T; How OJ; Myrmel T
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):75-87. PubMed ID: 32662299
[TBL] [Abstract][Full Text] [Related]
3. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
[TBL] [Abstract][Full Text] [Related]
4. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798
[TBL] [Abstract][Full Text] [Related]
5. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
Hoffmann LS; Schmidt PM; Keim Y; Schaefer S; Schmidt HH; Stasch JP
Br J Pharmacol; 2009 Jul; 157(5):781-95. PubMed ID: 19466990
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine 135 of the β
Rühle A; Elgert C; Hahn MG; Sandner P; Behrends S
Eur J Pharmacol; 2020 Aug; 881():173203. PubMed ID: 32446711
[TBL] [Abstract][Full Text] [Related]
7. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
Stasch JP; Hobbs AJ
Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
[TBL] [Abstract][Full Text] [Related]
8. Structural insights into the mechanism of human soluble guanylate cyclase.
Kang Y; Liu R; Wu JX; Chen L
Nature; 2019 Oct; 574(7777):206-210. PubMed ID: 31514202
[TBL] [Abstract][Full Text] [Related]
9. Soluble guanylate cyclase stimulators and their potential use: a patent review.
Sandner P; Vakalopoulos A; Hahn MG; Stasch JP; Follmann M
Expert Opin Ther Pat; 2021 Mar; 31(3):203-222. PubMed ID: 33395323
[No Abstract] [Full Text] [Related]
10. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
Breitenstein S; Roessig L; Sandner P; Lewis KS
Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
[TBL] [Abstract][Full Text] [Related]
11. A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGC.
Elgert C; Rühle A; Sandner P; Behrends S
Biochem Pharmacol; 2019 May; 163():142-153. PubMed ID: 30753814
[TBL] [Abstract][Full Text] [Related]
12. Allosteric activation of the nitric oxide receptor soluble guanylate cyclase mapped by cryo-electron microscopy.
Horst BG; Yokom AL; Rosenberg DJ; Morris KL; Hammel M; Hurley JH; Marletta MA
Elife; 2019 Sep; 8():. PubMed ID: 31566566
[TBL] [Abstract][Full Text] [Related]
13. Inhaled nitric oxide to control platelet hyper-reactivity in patients with acute submassive pulmonary embolism.
Kline JA; Puskarich MA; Pike JW; Zagorski J; Alves NJ
Nitric Oxide; 2020 Mar; 96():20-28. PubMed ID: 31940502
[TBL] [Abstract][Full Text] [Related]
14. Probing the Molecular Mechanism of Human Soluble Guanylate Cyclase Activation by NO in vitro and in vivo.
Pan J; Yuan H; Zhang X; Zhang H; Xu Q; Zhou Y; Tan L; Nagawa S; Huang ZX; Tan X
Sci Rep; 2017 Feb; 7():43112. PubMed ID: 28230071
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of the Soluble Guanylate Cyclase.
Makrynitsa GI; Zompra AA; Argyriou AI; Spyroulias GA; Topouzis S
Curr Med Chem; 2019; 26(15):2730-2747. PubMed ID: 30621555
[TBL] [Abstract][Full Text] [Related]
16. NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272.
Becker EM; Alonso-Alija C; Apeler H; Gerzer R; Minuth T; Pleiss U; Schmidt P; Schramm M; Schröder H; Schroeder W; Steinke W; Straub A; Stasch JP
BMC Pharmacol; 2001; 1():13. PubMed ID: 11801189
[TBL] [Abstract][Full Text] [Related]
17. Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor.
Montfort WR; Wales JA; Weichsel A
Antioxid Redox Signal; 2017 Jan; 26(3):107-121. PubMed ID: 26979942
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
19. Computational exploration of the binding mode of heme-dependent stimulators into the active catalytic domain of soluble guanylate cyclase.
Agulló L; Buch I; Gutiérrez-de-Terán H; Garcia-Dorado D; Villà-Freixa J
Proteins; 2016 Oct; 84(10):1534-48. PubMed ID: 27364190
[TBL] [Abstract][Full Text] [Related]
20. The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.
Sharina IG; Sobolevsky M; Papakyriakou A; Rukoyatkina N; Spyroulias GA; Gambaryan S; Martin E
Br J Pharmacol; 2015 May; 172(9):2316-29. PubMed ID: 25536881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
